4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
Source: SeekingAlpha
2025-12-17 12:59:04 ET
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential December 17, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
4D Molecular Therapeutics Inc.
NASDAQ: FDMT
FDMT Trading
0.47% G/L:
$8.4496 Last:
164,756 Volume:
$8.35 Open:
FDMT Latest News
FDMT Stock Data
$519,643,507
47,993,463
N/A
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
